These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
922 related articles for article (PubMed ID: 16703529)
1. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia]. Tanović A; Alfaro V Rev Neurol; 2006 May 16-31; 42(10):607-16. PubMed ID: 16703529 [TBL] [Abstract][Full Text] [Related]
8. Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation. Song MS; Rauw G; Baker GB; Kar S Eur J Neurosci; 2008 Nov; 28(10):1989-2002. PubMed ID: 19046381 [TBL] [Abstract][Full Text] [Related]
9. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. Parsons CG; Stöffler A; Danysz W Neuropharmacology; 2007 Nov; 53(6):699-723. PubMed ID: 17904591 [TBL] [Abstract][Full Text] [Related]
11. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies. Tariot PN J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847 [TBL] [Abstract][Full Text] [Related]
12. [The clinical relevance of memantine use]. Sobów T Psychiatr Pol; 2004; 38(2):321-30. PubMed ID: 15307296 [TBL] [Abstract][Full Text] [Related]
13. [Advanced dementia in Alzheimer's disease and memantine]. Alberca R Rev Neurol; 2005 Feb 1-15; 40(3):173-9. PubMed ID: 15750904 [TBL] [Abstract][Full Text] [Related]
14. Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity. Volbracht C; van Beek J; Zhu C; Blomgren K; Leist M Eur J Neurosci; 2006 May; 23(10):2611-22. PubMed ID: 16817864 [TBL] [Abstract][Full Text] [Related]
15. Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia. Müller WE; Mutschler E; Riederer P Pharmacopsychiatry; 1995 Jul; 28(4):113-24. PubMed ID: 7491365 [TBL] [Abstract][Full Text] [Related]
16. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope. Sonkusare SK; Kaul CL; Ramarao P Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530 [TBL] [Abstract][Full Text] [Related]
17. Management of moderate to severe Alzheimer's disease: focus on memantine. Dominguez E; Chin TY; Chen CP; Wu TY Taiwan J Obstet Gynecol; 2011 Dec; 50(4):415-23. PubMed ID: 22212311 [TBL] [Abstract][Full Text] [Related]
18. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Kornhuber J; Weller M Biol Psychiatry; 1997 Jan; 41(2):135-44. PubMed ID: 9018383 [TBL] [Abstract][Full Text] [Related]
19. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. Lipton SA J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416 [TBL] [Abstract][Full Text] [Related]
20. Mechanism of action of memantine. Johnson JW; Kotermanski SE Curr Opin Pharmacol; 2006 Feb; 6(1):61-7. PubMed ID: 16368266 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]